The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjectsDavid S. Small, Christopher D. Payne, Prajakti A. Kothare et al.|European Journal of Clinical Pharmacology|2009Cited by 75
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy chinese and white volunteers: An open-label trialDavid S. Small, Ronan P. Kelly, Christopher D. Payne et al.|Clinical Therapeutics|2010Cited by 47
A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).Shubham Pant, Manish R. Patel, Eunice Yuen et al.|Journal of Clinical Oncology|2019Cited by 24